. /.   WORLD TRADE  
ORGANIZATION  G/TBT/N/CAN/226 
29 January 2008 
 (08-0429) 
Committee on Technical Barriers to Trade Original:   English/ 
 French 
 
 
 
NOTIFICATION 
 
The following notification is being circ ulated in accordance with Article 10.6. 
 
1. Member to Agreement notifying:   CANADA  
If applicable, name of local government involved (Articles 3.2 and 7.2):         
2. Agency responsible:   Department of Health 
Name and address (including telephone and fax numbers, e-mail and web-site 
addresses, if available) of  agency or authority designated to handle comments 
regarding the notification shall be  indicated if different from above:    
Canadian Enquiry Point 
200-270 Albert Street Ottawa, Ontario Canada, K1P 6N7 
Tel.: (+1 613) 238 3222 
Fax.: (+1 613) 569 7808 E-mail: enquirypoint@scc.ca  
3. Notified under Article 2.9.2 [  X ], 2.10.1 [   ], 5.6.2 [   ], 5.7.1 [   ], other:         
4. Products covered (HS or CCCN where applicable, otherwise national tariff heading. 
ICS numbers may be provided in  addition, where applicable):   Prescription status of 
medicinal ingredients for veterinary use (ICS: 11.220) 
5. Title, number of pages and langua ge(s) of the notified document:   Proposed Amendment 
to the Food and Drug Regulations (Notice of Intent - Project No. 1554 - Schedule F)(2 pages, available in English and French) 
6. Description of content:   This Notice of Intent (NOI) is to provide an opportunity to 
comment on a proposed change in status of the medicinal ingredient progesterone in Schedule F to the Food and Drug Regulations .  
Progesterone is a hormone that is used in ve terinary medicine to treat conditions of the 
reproductive system in both farm animals and domestic pets.  Schedule F is a list of medicinal ingredients, the sale of which is controlled under sections 
C.01.041 to C.01.049 of the Food and Drug Regulations .  Part I of Schedule F lists 
ingredients that require a prescription for human use and for veterinary use.  Part II of 
Schedule F lists ingredients that require a prescription for human use, but do not require a 
prescription for veterinary use if so labelled or  if in a form unsuitable for human use.  
 G/TBT/N/CAN/226 
Page 2  
 
  Progesterone is currently included in Part II of Schedule F in the group listing for sex 
hormones, which means that a prescription is required for progesterone for human use but 
not for veterinary use.  The proposed change  in status means that progesterone would 
require a prescription for both human and veteri nary use except when sold in an implant for 
veterinary use for growth promotion.  
7. Objective and rationale, including the na ture of urgent problems where applicable:  
Protection of animal health 
8. Relevant documents:   Canada Gazette, Part I, 19 Ja nuary 2008, Pages 121-122 (available 
in English and French) 
9. Proposed date of adoption:  Normally within 6 to 8 months of publication in the Canada 
Gazette, Part I. 
Proposed date of entry into force:  On the date the measure is adopted. 
10. Final date for comments:   3 April 2008 
11. Texts available from:  National enquiry point [  X ] or address, telephone and fax 
numbers, e-mail and web-site addresses,  if available of the other body:  The electronic 
version of the Notice of Intent can be downloaded at:   http://canadagazette.gc.ca/partI/2008/20080119/pdf/g1-14203.pdf
 (Canada Gazette) 
or 
http://canadagazette.gc.ca/partI/2008/20080119/html/notice-e.html#i16 (English) 
http://canadagazette.gc.ca/partI/2008/20080119/html/notice-f.html#i16 (French)